Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma
Open Access
- 5 August 2026
- journal article
- review article
- Published by Wiley in Cancer Reports
- Vol. 9 (8) , e70643
Abstract
Background: Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways, could decrease treatment efficacy. Drug repurposing offers an attractive strategy to identify agents that may enhance TMZ activity because these drugs already have known pharmacokinetic and safety profiles. This narrative review summarizes the available evidence on repurposed drugs investigated as potential modulators of TMZ response in GB. Recent Findings: A range of repurposed agents, including chloroquine, valproic acid, levetiracetam, metformin, aspirin, amlodipine, atorvastatin, chlorpromazine, melatonin, disulfiram, bortezomib, and verteporfin, have been evaluated in GB models and selected clinical studies. Reported mechanisms include modulation of MGMT expression, autophagy, oxidative stress, apoptosis, DNA‐damage responses, cancer stem‐cell properties, and signaling pathways such as PI3K/AKT/mTOR, AMPK, EGFR, STAT3, ERK1/2, and NF‐κB. Several agents have enhanced TMZ‐associated cytotoxicity in cell culture and animal models. However, clinical evidence remains limited, and the results are inconsistent for some drugs. Blood–brain barrier penetration, achievable intratumoral drug exposure, toxicity, treatment scheduling, and molecular heterogeneity of GB remain major translational challenges. Conclusion: Repurposed drugs may provide useful candidates for improving TMZ‐based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood–brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well‐designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment.Keywords
This publication has 112 references indexed in Scilit:
- Stereoselective study of fluoxetine and norfluoxetine across the blood–brain barrier mediated by organic cation transporter 1/3 in rats using an enantioselective UPLC‐MS/MS methodChirality, 2023
- Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling of Diazepam: Unbound Interstitial Brain Concentrations Correspond to Clinical End PointsThe Journal of Clinical Pharmacology, 2022
- d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitroCancer Chemotherapy and Pharmacology, 2019
- Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade gliomaEuropean Journal of Clinical Pharmacology, 2016
- Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulationJournal of Molecular Medicine, 2011
- Effect of aminophylline on aspirin penetration into the central nervous system in ratsEuropean Journal of Drug Metabolism and Pharmacokinetics, 2008
- Many faces of NF-κB signaling induced by genotoxic stressJournal of Molecular Medicine, 2007
- Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood?brain barrier of Abcb1a gene knockout micePsychopharmacology, 2004
- Mechanisms of the Deleterious Effects of Tamoxifen on Mitochondrial Respiration Rate and Phosphorylation EfficiencyToxicology and Applied Pharmacology, 2001
- Dual Effect of Tamoxifen, an Anti-Breast-Cancer Drug, on Intracellular Ca2+ and Cytotoxicity in Intact CellsToxicology and Applied Pharmacology, 2000